M Varosanec1, T Uher2, D Horakova3, J Hagemeier1, N Bergsland4, M Tyblova3, Z Seidl5, M Vaneckova5, J Krasensky5, M G Dwyer1, E Havrdova3, R Zivadinov6. 1. From the Buffalo Neuroimaging Analysis Center (M.V., T.U., J.H., N.B., M.G.D., R.Z.), Department of Neurology, University at Buffalo SUNY, Buffalo, New York. 2. From the Buffalo Neuroimaging Analysis Center (M.V., T.U., J.H., N.B., M.G.D., R.Z.), Department of Neurology, University at Buffalo SUNY, Buffalo, New York Department of Neurology and Center of Clinical Neuroscience (T.U., D.H., M.T., E.H.). 3. Department of Neurology and Center of Clinical Neuroscience (T.U., D.H., M.T., E.H.). 4. From the Buffalo Neuroimaging Analysis Center (M.V., T.U., J.H., N.B., M.G.D., R.Z.), Department of Neurology, University at Buffalo SUNY, Buffalo, New York IRCCS "Santa Maria Nascente" (N.B.), Don Gnocchi Foundation, Milan, Italy. 5. Department of Radiology (Z.S., M.V., J.K.), Charles University in Prague, First Faculty of Medicine and General University Hospital, Prague, Czech Republic. 6. From the Buffalo Neuroimaging Analysis Center (M.V., T.U., J.H., N.B., M.G.D., R.Z.), Department of Neurology, University at Buffalo SUNY, Buffalo, New York rzivadinov@bnac.net.
Abstract
BACKGROUND AND PURPOSE: The relationship between lesion formation and brain atrophy development in the early phase of multiple sclerosis is unclear. We investigated the association between new lesion accumulation and brain atrophy progression in patients with clinically isolated syndrome over 48 months. MATERIALS AND METHODS: Patients with clinically isolated syndrome (n = 210) were evaluated with 1.5T MR imaging at baseline and at 6, 12, 24, 36, and 48 months as part of a multicenter observational study of early administration of intramuscular interferon β-1a. Mixed-effect model analyses, adjusted for age, sex, and treatment status, investigated the association between accumulation of contrast-enhancing and T2 lesions and brain-volume percent changes in a 48-month period. RESULTS: In patients with clinically isolated syndrome, the average whole-brain volume decreased 2.5%, the mean lateral ventricle volume increased 16.9%, and a mean of 7.7 new/enlarging T2 lesions accumulated over the follow-up period. Patients with clinically isolated syndrome who showed greater percentages of change in whole-brain, white and gray matter, cortical, and lateral ventricle volumes over the follow-up period had more severe lesion outcomes at baseline (all P < .007). There were significant associations between decreased individual brain-volume measures at baseline and greater percentages of change during follow-up (P < .05). We found a significant association between the total cumulative number of new/enlarging T2 lesions and the evolution of whole-brain (P < .001), lateral ventricle (P = .007), gray matter and thalamic (P = .013), subcortical deep gray matter (P = .015), and cortical (P = .036) volumes over the follow-up period. CONCLUSIONS: Lesion accumulation and brain-volume changes occur simultaneously in the early phase of clinically isolated syndrome. More severe lesion and brain-volume outcomes at baseline were associated with greater development of brain atrophy over the follow-up period in patients with clinically isolated syndrome.
BACKGROUND AND PURPOSE: The relationship between lesion formation and brain atrophy development in the early phase of multiple sclerosis is unclear. We investigated the association between new lesion accumulation and brain atrophy progression in patients with clinically isolated syndrome over 48 months. MATERIALS AND METHODS:Patients with clinically isolated syndrome (n = 210) were evaluated with 1.5T MR imaging at baseline and at 6, 12, 24, 36, and 48 months as part of a multicenter observational study of early administration of intramuscular interferon β-1a. Mixed-effect model analyses, adjusted for age, sex, and treatment status, investigated the association between accumulation of contrast-enhancing and T2 lesions and brain-volume percent changes in a 48-month period. RESULTS: In patients with clinically isolated syndrome, the average whole-brain volume decreased 2.5%, the mean lateral ventricle volume increased 16.9%, and a mean of 7.7 new/enlarging T2 lesions accumulated over the follow-up period. Patients with clinically isolated syndrome who showed greater percentages of change in whole-brain, white and gray matter, cortical, and lateral ventricle volumes over the follow-up period had more severe lesion outcomes at baseline (all P < .007). There were significant associations between decreased individual brain-volume measures at baseline and greater percentages of change during follow-up (P < .05). We found a significant association between the total cumulative number of new/enlarging T2 lesions and the evolution of whole-brain (P < .001), lateral ventricle (P = .007), gray matter and thalamic (P = .013), subcortical deep gray matter (P = .015), and cortical (P = .036) volumes over the follow-up period. CONCLUSIONS: Lesion accumulation and brain-volume changes occur simultaneously in the early phase of clinically isolated syndrome. More severe lesion and brain-volume outcomes at baseline were associated with greater development of brain atrophy over the follow-up period in patients with clinically isolated syndrome.
Authors: Stephen M Smith; Yongyue Zhang; Mark Jenkinson; Jacqueline Chen; P M Matthews; Antonio Federico; Nicola De Stefano Journal: Neuroimage Date: 2002-09 Impact factor: 6.556
Authors: N De Stefano; A Giorgio; M Battaglini; M Rovaris; M P Sormani; F Barkhof; T Korteweg; C Enzinger; F Fazekas; M Calabrese; D Dinacci; G Tedeschi; A Gass; X Montalban; A Rovira; A Thompson; G Comi; D H Miller; M Filippi Journal: Neurology Date: 2010-06-08 Impact factor: 9.910
Authors: Tomas Uher; Jana Blahova-Dusankova; Dana Horakova; Niels Bergsland; Michaela Tyblova; Ralph H B Benedict; Tomas Kalincik; Deepa P Ramasamy; Zdenek Seidl; Jesper Hagermeier; Manuela Vaneckova; Jan Krasensky; Eva Havrdova; Robert Zivadinov Journal: J Neurol Date: 2014-06-22 Impact factor: 4.849
Authors: Robert Zivadinov; Mari Heininen-Brown; Claudiu V Schirda; Guy U Poloni; Niels Bergsland; Christopher R Magnano; Jacqueline Durfee; Cheryl Kennedy; Ellen Carl; Jesper Hagemeier; Ralph H B Benedict; Bianca Weinstock-Guttman; Michael G Dwyer Journal: Neuroimage Date: 2011-07-27 Impact factor: 6.556
Authors: Robert Zivadinov; Eva Havrdová; Niels Bergsland; Michaela Tyblova; Jesper Hagemeier; Zdenek Seidl; Michael G Dwyer; Manuela Vaneckova; Jan Krasensky; Ellen Carl; Tomas Kalincik; Dana Horáková Journal: Radiology Date: 2013-04-23 Impact factor: 11.105
Authors: Tomas Uher; Dana Horakova; Niels Bergsland; Michaela Tyblova; Deepa P Ramasamy; Zdenek Seidl; Manuela Vaneckova; Jan Krasensky; Eva Havrdova; Robert Zivadinov Journal: Neuroimage Clin Date: 2014-09-28 Impact factor: 4.881
Authors: Tomas Uher; Jan Krasensky; Charles Malpas; Niels Bergsland; Michael G Dwyer; Eva Kubala Havrdova; Manuela Vaneckova; Dana Horakova; Robert Zivadinov; Tomas Kalincik Journal: Neurol Neuroimmunol Neuroinflamm Date: 2021-03-16
Authors: Mark A Espeland; Kirk Erickson; Rebecca H Neiberg; John M Jakicic; Thomas A Wadden; Rena R Wing; Lisa Desiderio; Guray Erus; Meng-Kang Hsieh; Christos Davatzikos; Barbara J Maschak-Carey; Paul J Laurienti; Kathryn Demos-McDermott; R Nick Bryan Journal: Diabetes Care Date: 2016-03-29 Impact factor: 19.112